Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390531 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
A Phase 1 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT02390531 is a Phase 1 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 120 participants.
The verdict
NCT02390531, a Phase 1 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to find a dose of intravitreal bevacizumab that is lower than currently used for severe retinopathy of prematurity (ROP), is effective in this study, and can be tested in future larger studies.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390531
The ClinicalTrials.gov registry entry for NCT02390531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT02390531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390531 about?
NCT02390531 is a clinical study titled "Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity". The purpose of this study is to find a dose of intravitreal bevacizumab that is lower than currently used for severe retinopathy of prematurity (ROP), is effective in this study, and can be tested in future larger studies.
What is the current status of trial NCT02390531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2015-04-28. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT02390531?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02390531?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.